Physician profile
Brian A Hemann
NPI 1316048648
$6,455.83
in general payments reported to CMS, 2019-2025
34 companies · $1,502 in 2025
The $1,502 reported for 2025 was more than what 78% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $52.18 · 2021: $896 · 2022: $1,712 · 2023: $973 · 2024: $1,320 · 2025: $1,502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,777 · Consulting Fee: $18.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,776.98 |
| Consulting Fee | $18.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $589.93 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Medtronic, INC. | $586.93 | 2021-2023 | Cobalt Dr Mri Surescan, Corevalve Evolut R, Linq II |
| E.R. Squibb & Sons, L.L.C. | $532.82 | 2021-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $478.41 | 2021-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Aveir |
| Atricure, INC. | $466.97 | 2021-2024 | |
| Amgen INC. | $456.90 | 2022-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $369.54 | 2021-2024 | Xarelto |
| Boston Scientific Corporation | $320.14 | 2022-2025 | Watchman Flx |
| Novartis Pharmaceuticals Corporation | $273.11 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $238.06 | 2022-2025 | Verquvo |
| Edwards Lifesciences Corporation | $234.19 | 2023-2024 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Heartflow, INC. | $197.91 | 2023-2025 | Ffrct |
| Baxter Healthcare | $182.96 | 2023-2025 | Hillrom - Carnation Ambulatory Monitor |
| Sanofi-Aventis U.S. LLC | $151.14 | 2022-2024 | |
| Cvrx, INC. | $149.17 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $131.90 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.68 | 2022-2025 | Jardiance |
| Bardy Diagnostics, INC. | $118.83 | 2022 | |
| Pfizer INC. | $117.43 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $108.84 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $105.90 | 2021-2025 | Farxiga |
| Kiniksa Pharmaceuticals International, Plc | $94.19 | 2024 | Arcalyst |
| Philips North America LLC | $72.44 | 2022-2024 | (Ck4) Mcot |
| Acutus Medical, INC. | $52.18 | 2020 | |
| Medicomp INC | $45.95 | 2024 | Telepatch Cardiac Monitor |
| Esperion Therapeutics, INC. | $41.64 | 2025 | Nexletol |
| Ge Healthcare | $40.62 | 2021 | |
| Corvista Health, INC. | $30.74 | 2025 | Corvista System |
| Alnylam Pharmaceuticals INC. | $29.51 | 2025 | Amvuttra |
| Abiomed | $29.05 | 2024 | Impella |
| Actelion Pharmaceuticals US, INC. | $23.17 | 2024 | Opsumit |
| Bridgebio Pharma, INC. | $21.39 | 2025 | Attruby |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $17.16 | 2023 | Lifevest |
| Chiesi USA, INC. | $16.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Hemann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.